Zacks.com on MSN10h
Boston Scientific Stock Set to Gain From Completion of Axonics Deal
Boston Scientific Corporation BSX recently closed the acquisition of Axonics, Inc., a medical technology company focused on the development and commercialization of differentiated devices to treat ...
FierceBiotech7h
AHA 2024: Boston Scientific, Abbott tout long-term heart occluder data
Abbott’s Amulet IDE trial put its left atrial appendage closure device up against the Watchman 2.5, which was approved by the ...
GlobalData on MSN1d
Boston Scientific reports outcomes from trial of LAAC device
The trial met its primary safety and efficacy endpoints, demonstrating the device's superiority to oral anticoagulants.
Boston Scientific’s WATCHMAN FLX: Poised for Growth with New Trial Results and Reimbursement Code
Mizuho Securities analyst Anthony Petrone has maintained their bullish stance on BSX stock, giving a Buy rating yesterday.Don't Miss our Black ...
health.economictimes.indiatimes12h
Boston Scientific launches multi-functional imaging system AVVIGO
AVVIGO is an intravascular ultrasound (IVUS) and fractional flow reserve (FFR) system designed to provide high-quality IVUS ...
MassDevice4d
Boston Scientific finalizes $3.7B acquisition of Axonics
Boston Scientific (NYSE: BSX) today announced the completion of its $3.7 billion acquisition of Axonics, Inc. (Nasdaq: AXNX).
Orange County Business Journal1d
Boston Scientific Completes $3.7B Acquisition of Axonics
Boston Scientific Corp. last week announced that it has closed on its acquisition of Irvine-based medical device maker ...
Pharmabiz11h
Boston Scientific WATCHMAN FLX LAAC device demonstrates superior bleeding risk reduction to OAC following a cardiac ablation in OPTION clinical trial
Marlborough, Massachusetts Tuesday, November 19, 2024, 17:00 Hrs [IST] ...